JMI Laboratories, North Liberty, Iowa, USA
JMI Laboratories, North Liberty, Iowa, USA.
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00313-18. Print 2018 Aug.
Plazomicin and comparator agents were tested by using the CLSI reference broth microdilution method against 4,825 clinical isolates collected during 2014 and 2015 in 70 U.S. hospitals as part of the ALERT (Antimicrobial Longitudinal Evaluation and Resistance Trends) program. Plazomicin (MIC/MIC, 0.5/2 μg/ml) inhibited 99.2% of 4,362 at ≤4 μg/ml. Amikacin, gentamicin, and tobramycin inhibited 98.9%, 90.3%, and 90.3% of these isolates, respectively, by applying CLSI breakpoints. The activities of plazomicin were similar among species, with MIC values ranging from 0.25 to 1 μg/ml, with the exception of and indole-positive that displayed MIC values of 2 μg/ml. For 97 carbapenem-resistant (CRE), which included 87 isolates carrying , plazomicin inhibited all but 1 isolate at ≤2 μg/ml (99.0% and 98.9%, respectively). Amikacin and gentamicin inhibited 64.9% and 56.7% of the CRE isolates at the respective CLSI breakpoints. Plazomicin inhibited 96.5 and 95.5% of the gentamicin-resistant isolates, 96.9 and 96.5% of the tobramycin-resistant isolates, and 64.3 and 90.0% of the amikacin-resistant isolates according to CLSI and EUCAST breakpoints, respectively. The activities of plazomicin against (MIC/MIC, 4/16 μg/ml) and species (MIC/MIC, 2/16 μg/ml) isolates were similar. Plazomicin was active against coagulase-negative staphylococci (MIC/MIC, 0.12/0.5 μg/ml) and (MIC/MIC, 0.5/0.5 μg/ml) but had limited activity against spp. (MIC/MIC, 16/64 μg/ml) and (MIC/MIC, 32/64 μg/ml). Plazomicin activity against the tested, including CRE and isolates carrying from U.S. hospitals, supports the development plan for plazomicin to treat serious infections caused by resistant in patients with limited treatment options.
-plazomicin 和比较剂通过 CLSI 参考肉汤微量稀释法对 4825 株临床分离株进行测试，这些分离株是在 2014 年至 2015 年期间在美国 70 家医院的 ALERT（抗菌纵向评估和耐药趋势）计划中收集的。plazomicin（MIC/MIC，0.5/2μg/ml）抑制了 4362 株≤4μg/ml 的 株的 99.2%。阿米卡星、庆大霉素和妥布霉素分别通过 CLSI 折点抑制了 98.9%、90.3%和 90.3%的这些分离株。plazomicin 在 种间的活性相似，MIC 值范围为 0.25-1μg/ml，除 MIC 值为 2μg/ml 的 和吲哚阳性 外。对于 97 株碳青霉烯类耐药 （CRE），包括 87 株携带 的 CRE，plazomicin 抑制了除 1 株外的所有 CRE 株，其 MIC 值均为≤2μg/ml（分别为 99.0%和 98.9%）。阿米卡星和庆大霉素分别抑制了 64.9%和 56.7%的 CRE 分离株。根据 CLSI 和 EUCAST 折点，plazomicin 分别抑制了 64.3%和 90.0%的氨基糖苷类耐药分离株、96.9%和 96.5%的妥布霉素耐药分离株、96.5%和 95.5%的庆大霉素耐药分离株。plazomicin 对 （MIC/MIC，4/16μg/ml）和 种（MIC/MIC，2/16μg/ml）分离株的活性相似。plazomicin 对凝固酶阴性葡萄球菌（MIC/MIC，0.12/0.5μg/ml）和 （MIC/MIC，0.5/0.5μg/ml）具有活性，但对 spp.（MIC/MIC，16/64μg/ml）和 （MIC/MIC，32/64μg/ml）的活性有限。plazomicin 对美国医院分离的耐碳青霉烯 株和携带 的 CRE 株的活性支持了 plazomicin 的开发计划，以治疗对治疗选择有限的耐药 引起的严重感染。
